Quimidroga targets Europe growth, margin recovery after 44% profit drop

Family-owned Spanish capital group Quimidroga, focused on life sciences, reported a 44% decline in 2025 earnings on revenue of €1.065 million. Management expects improved results this year, citing growth in Europe and margin enhancement. The profit drop signals operational headwinds, but the forward outlook suggests stabilization.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works